Biologic use in AS more than doubles in a decade


A large rise in the use of biologics in ankylosing spondylitis over the last decade can be explained by an increased awareness of inflammatory back pain and a reluctance to stop therapy in patients who have partially responded to treatment, a PBS review concludes. According to an outcomes statement from the the PBS drug utilisation ...


Already a member? Login to keep reading


OR
© 2017 the limbic